MDT
86.18
+0.38%↑
A
114.89
+0.93%↑
VEEV
174.14
-0.8%↓
HQY
83.51
+0.14%↑
PHR.US
8.67
+8.24%↑
MDT
86.18
+0.38%↑
A
114.89
+0.93%↑
VEEV
174.14
-0.8%↓
HQY
83.51
+0.14%↑
PHR.US
8.67
+8.24%↑
MDT
86.18
+0.38%↑
A
114.89
+0.93%↑
VEEV
174.14
-0.8%↓
HQY
83.51
+0.14%↑
PHR.US
8.67
+8.24%↑
MDT
86.18
+0.38%↑
A
114.89
+0.93%↑
VEEV
174.14
-0.8%↓
HQY
83.51
+0.14%↑
PHR.US
8.67
+8.24%↑
MDT
86.18
+0.38%↑
A
114.89
+0.93%↑
VEEV
174.14
-0.8%↓
HQY
83.51
+0.14%↑
PHR.US
8.67
+8.24%↑
24h
Corrente
Minimo
4.04
Massimo
4.58
Raccomandazioni | Acquista |
|---|---|
Previsioni per 12 mesi | +430.3% upside |
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
31 mar 2026, 23:31 UTC
Stocks to Watch: Nike, RH, NCino
DJ
LeggI
31 mar 2026, 22:35 UTC
Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update
DJ
LeggI
1 apr 2026, 00:00 UTC
The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ
DJ
LeggI
31 mar 2026, 23:50 UTC
Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO
DJ
LeggI
31 mar 2026, 23:43 UTC
Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk
DJ
LeggI
31 mar 2026, 23:33 UTC
Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk
DJ
LeggI
31 mar 2026, 23:21 UTC
Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com
DJ
LeggI
31 mar 2026, 23:14 UTC
Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk
DJ
LeggI
31 mar 2026, 23:12 UTC
Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk
DJ
LeggI
31 mar 2026, 22:36 UTC
China Vanke 2025 Loss Widens >000002.SZ
DJ
LeggI
31 mar 2026, 22:36 UTC
China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ
DJ
LeggI
31 mar 2026, 22:36 UTC
China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ
DJ
LeggI
31 mar 2026, 22:36 UTC
China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ
DJ
LeggI
31 mar 2026, 22:36 UTC
China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ
DJ
LeggI
31 mar 2026, 21:46 UTC
Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ
DJ
LeggI
31 mar 2026, 21:36 UTC
West African Resources's Costs Higher Than Bull Expected -- Market Talk
DJ
LeggI
31 mar 2026, 21:35 UTC
Nike Expects China Sales Down 20% in 4Q, CFO Says
DJ
LeggI
31 mar 2026, 21:35 UTC
Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says
DJ
LeggI
31 mar 2026, 21:35 UTC
Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says
DJ
LeggI
31 mar 2026, 21:33 UTC
Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com
DJ
LeggI
31 mar 2026, 21:33 UTC
Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says
DJ
LeggI
31 mar 2026, 21:32 UTC
Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says
DJ
LeggI
31 mar 2026, 21:28 UTC
Nike Expects to End 4Q With Elevated Inventory, CFO Says
DJ
LeggI
31 mar 2026, 21:26 UTC
Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says
DJ
LeggI
31 mar 2026, 21:25 UTC
Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says
DJ
LeggI
31 mar 2026, 21:24 UTC
Nike: Turnaround Plan Progressing at Different Rates -- Market Talk
DJ
LeggI
31 mar 2026, 21:22 UTC
Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters
DJ
LeggI
31 mar 2026, 21:22 UTC
Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says
DJ
LeggI
31 mar 2026, 21:21 UTC
Nike's Digital Channel Still Too Promotional, CFO Says
DJ
LeggI
31 mar 2026, 21:20 UTC
Nike CEO: Converse Remains Important to Portfolio
DJ
LeggI
Modifica del prezzo
By TipRanks
Previsioni per 12 mesi
Media 21 USD 430.3%
Alto 21 USD
Basso 21 USD
Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Aptevo Therapeutics Inc - Dist negli ultimi 3 mesi.
By TipRanks
Acquista
1 ratings
1
Acquista
0
Mantieni
0
Vendi
Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Aptevo Therapeutics Inc - Dist negli ultimi 3 mesi.
$